Contraindications
- Hypersensitivity
Dosing: Adult
- Gastric ulcer: 100 mg three times daily (morning, evening, bedtime)
- Gastric mucosal lesions in acute gastritis or acute exacerbation of chronic gastritis: 100 mg three times daily
Dosing: Altered kidney function
Rebamipide is a gastric mucosal protectant; about 10% of a dose appears in urine. In kidney impairment, single-dose levels are higher and the half-life longer, but the Japanese insert reports no accumulation with repeated dosing in dialysis patients and sets no kidney dose change. It has no US FDA label.
Kidney function measure: The Japanese insert describes kidney impairment and dialysis without numeric thresholds or dose changes; bands shown on creatinine clearance (CrCl).
Show full dosing details
- CrCl ≥60 mL/min
- Usual: 100 mg three times daily (morning, evening and at bedtime for gastric ulcer) (PMDA insert).
- CrCl 30–59 mL/min
- The Japanese insert gives no dose change and has no kidney-impairment caution section (no section 9.2). Levels were higher and the half-life longer after a single 100 mg dose in kidney impairment; steady-state levels in dialysis patients matched single-dose predictions, so no accumulation is expected (PMDA insert 16.6.1).
- CrCl 15–29 mL/min
- The Japanese insert gives no dose change and has no kidney-impairment caution section (no section 9.2). Levels were higher and the half-life longer after a single 100 mg dose in kidney impairment; steady-state levels in dialysis patients matched single-dose predictions, so no accumulation is expected (PMDA insert 16.6.1).
- CrCl <15 mL/min (not on dialysis)
- The Japanese insert gives no dose change and has no kidney-impairment caution section (no section 9.2). Levels were higher and the half-life longer after a single 100 mg dose in kidney impairment; steady-state levels in dialysis patients matched single-dose predictions, so no accumulation is expected (PMDA insert 16.6.1).
- Hemodialysis (intermittent)
- No dose change; steady-state levels in dialysis patients matched single-dose predictions (no accumulation) (PMDA insert).
- Peritoneal dialysis
- No PD data.
- CRRT
- No data.
- Dialyzable? Not stated (98.4% to 98.6% protein-bound).
- Monitoring Liver tests and blood counts if symptoms (hepatic dysfunction, jaundice, leukopenia, thrombocytopenia reported); stop if marked transaminase rise with fever and rash (PMDA insert).
Children (kidney dosing)
- eGFR ≥60
- Not established in children; kidney dosing not applicable.
- eGFR 30–59
- Not established in children; kidney dosing not applicable.
- eGFR 15–29
- Not established in children; kidney dosing not applicable.
- eGFR <15 (not on dialysis)
- Not established in children; kidney dosing not applicable.
- Hemodialysis (intermittent)
- Not established in children; kidney dosing not applicable.
- Peritoneal dialysis
- Not established in children; kidney dosing not applicable.
- CRRT
- Not established in children; kidney dosing not applicable.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Source: PMDA (Japan) product information (October 2023). This generic has no US FDA label.
Dosing: Pediatric
- Approved ages
- No pediatric trials (PMDA insert).
- Usual dose
- Not established.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedDosage forms
Philippines
- Film-coated tablet: 100 mg
- Tablet: 100 mg
Registered products in the Philippines
5 products registered with the Food and Drug Administration (FDA) Philippines list Rebamipide as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products5
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
MucopidRebamipide | 100 mg Film Coated TabletAlu/PVC Blister Pack of 10's Box of 100's | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | Ritemed Phils., Inc. | DRP-8194 | May 15, 2029 | |
MucoproRebamipide | 100 mg TabletAlu/PVC Blister Pack x 10's (Box of 30's) | Rx | Kyung Dong Pharm Co., Ltd.Republic of Korea | Kaufmann Pharma Inc. | DRP-3797 | May 9, 2031 | |
MUCOSTAREBAMIPIDE | 100 mg TABLET | Rx | KOREA OTSUKA PHARMACEUTICAL CO., LTD. | — | DRP-6291 | Nov 21, 2026 | |
Rebamid 100Rebamipide | 100 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Unison Laboratories Co., Ltd.Thailand | Justright Healthcare Inc. | DR-XY48673 | Jun 6, 2028 | |
RemastaRebamipide | 100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Myungmoon Pharm. Co., Ltd.Republic of Korea | The Cathay Drug Co., Inc. | DR-XY42872 | Oct 25, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Adverse reactions
Common
- Rash, pruritus
- Constipation, bloating, diarrhea, nausea
Serious
- Shock, anaphylaxis
- Leukopenia, thrombocytopenia
- Hepatic dysfunction, jaundice
Monitoring parameters
- Liver tests and blood counts if symptoms (hepatic dysfunction, jaundice, leukopenia, thrombocytopenia reported); stop if marked transaminase rise with fever and rash (PMDA insert). Kidney
- Liver tests and blood counts if symptomatic
Pharmacokinetics
Key PK parameters
| Time to peak | 2.4 hours (100 mg fasting) |
|---|---|
| Half-life | 1.9 hours |
| Half-life in kidney failure (ESKD) kidney | Prolonged after a single dose; no accumulation on dialysis |
| Protein binding | 98.4% to 98.6% |
| Metabolism (CYP, transporters) | Minimal (8-hydroxy metabolite about 0.03%; CYP3A4 in vitro) |
| Renal excretion kidney | About 10% of a dose in urine, mostly unchanged |
| Dialyzability kidney | Not stated |
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Pharmaceuticals and Medical Devices Agency (Japan). Rebamipide tablets 100 mg "NP" package insert [PMDA (Japan) product information, October 2023; no US FDA label]. https://www.pmda.go.jp/PmdaSearch/bookSearch/01/04987190646606
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- Nipro Corporation. (2023). Rebamipide tablets 100 mg "NP" [Japanese package insert, 1st edition, revised October 2023]. Pharmaceuticals and Medical Devices Agency (PMDA), Japan. https://www.pmda.go.jp/PmdaSearch/bookSearch/01/04987190646606
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .